Aratana Therapeutics Announces Positive Results for AT-003


Results from the study in client-owned cats undergoing an elective onychectomy showed bupivacaine liposome injectable suspension met protocol-defined efficacy success criteria, which were statistically significant (p < 0.05). Separately, in June, the Company submitted results from the pivotal safety study to FDA s Center for Veterinary Medicine (CVM) for AT-003 in cats. Data from both studies [ ] The post Aratana Therapeutics Announces Positive Results for AT-003 appeared first on STL News.
http://bit.ly/2u9ZKSl

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Create a website or blog at WordPress.com

Up ↑

%d bloggers like this: